BiotechTube

Meningococcal C conjugate vaccine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Prevention of Meningococcal Infection

Conditions

Prevention of Meningococcal Infection

Trial Timeline

Feb 1, 2005 → Oct 1, 2005

NCT ID
NCT00316654

About Meningococcal C conjugate vaccine

Meningococcal C conjugate vaccine is a approved stage product being developed by Novartis for Prevention of Meningococcal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00316654. Target conditions include Prevention of Meningococcal Infection.

What happened to similar drugs?

8 of 20 similar drugs in Prevention of Meningococcal Infection were approved

Approved (8) Terminated (0) Active (12)
✅RaltegravirMerckApproved
✅Meningococcal C conjugate vaccineNovartisApproved
✅Boostrix + Placebo (Saline)NovartisApproved
✅Meningococcal C conjugate vaccineNovartisApproved
✅Lenacapavir long-actingGilead SciencesApproved
✅DescovyGilead SciencesApproved
✅13-valent Pneumococcal conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT00310713ApprovedCompleted
NCT00311415Phase 3Completed
NCT00310635ApprovedCompleted
NCT00310700ApprovedCompleted
NCT00316654ApprovedCompleted
NCT00310674Phase 3Completed

Competing Products

20 competing products in Prevention of Meningococcal Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1944ModernaPhase 1
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
MifepristoneEli LillyPhase 2
35
EXANTAAstraZenecaPhase 2
27
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26
DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3
40
Esomeprazole + PlaceboAstraZenecaPhase 3
40
PCV15MerckPre-clinical
18
RaltegravirMerckApproved
43
RotaTeq (V260) + IPVMerckPhase 3
40
V501MerckPhase 3
40
ZostavaxMerckPhase 3
40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
40
Letermovir + PlaceboMerckPhase 3
40
Enteric-coated mycophenolate sodiumNovartisPhase 3
40
Meningococcal C conjugate vaccineNovartisApproved
43
rMenB+OMV NZNovartisPhase 3
40
Enteric-Coated Mycophenolate SodiumNovartisPhase 3
40
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5mlNovartisPhase 3
44